607 related articles for article (PubMed ID: 21490603)
1. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.
Reaper PM; Griffiths MR; Long JM; Charrier JD; Maccormick S; Charlton PA; Golec JM; Pollard JR
Nat Chem Biol; 2011 Apr; 7(7):428-30. PubMed ID: 21490603
[TBL] [Abstract][Full Text] [Related]
2. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated.
Kennedy RD; Chen CC; Stuckert P; Archila EM; De la Vega MA; Moreau LA; Shimamura A; D'Andrea AD
J Clin Invest; 2007 May; 117(5):1440-9. PubMed ID: 17431503
[TBL] [Abstract][Full Text] [Related]
3. Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.
Williamson CT; Kubota E; Hamill JD; Klimowicz A; Ye R; Muzik H; Dean M; Tu L; Gilley D; Magliocco AM; McKay BC; Bebb DG; Lees-Miller SP
EMBO Mol Med; 2012 Jun; 4(6):515-27. PubMed ID: 22416035
[TBL] [Abstract][Full Text] [Related]
4. The antiproliferative effects of ataxia-telangiectasia mutated and ATM- and Rad3-related inhibitions and their enhancements with the cytotoxicity of DNA damaging agents in cholangiocarcinoma cells.
Moolmuang B; Ruchirawat M
J Pharm Pharmacol; 2021 Mar; 73(1):40-51. PubMed ID: 33791808
[TBL] [Abstract][Full Text] [Related]
5. Relationship between DNA double-strand break rejoining and cell survival after exposure to ionizing radiation in human fibroblast strains with differing ATM/p53 status: implications for evaluation of clinical radiosensitivity.
Mirzayans R; Severin D; Murray D
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1498-505. PubMed ID: 17126209
[TBL] [Abstract][Full Text] [Related]
6. Induction of p53 renders ATM-deficient mice refractory to hepatocarcinogenesis.
Teoh N; Pyakurel P; Dan YY; Swisshelm K; Hou J; Mitchell C; Fausto N; Gu Y; Farrell G
Gastroenterology; 2010 Mar; 138(3):1155-65.e1-2. PubMed ID: 19919837
[TBL] [Abstract][Full Text] [Related]
7. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis.
Pabla N; Huang S; Mi QS; Daniel R; Dong Z
J Biol Chem; 2008 Mar; 283(10):6572-83. PubMed ID: 18162465
[TBL] [Abstract][Full Text] [Related]
8. The alkylating carcinogen N-methyl-N'-nitro-N-nitrosoguanidine activates the plasminogen activator inhibitor-1 gene through sequential phosphorylation of p53 by ATM and ATR kinases.
Vidal B; Parra M; Jardí M; Saito S; Appella E; Muñoz-Cánoves P
Thromb Haemost; 2005 Mar; 93(3):584-91. PubMed ID: 15735814
[TBL] [Abstract][Full Text] [Related]
9. Distinct roles of ATR and DNA-PKcs in triggering DNA damage responses in ATM-deficient cells.
Tomimatsu N; Mukherjee B; Burma S
EMBO Rep; 2009 Jun; 10(6):629-35. PubMed ID: 19444312
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.
Charrier JD; Durrant SJ; Golec JM; Kay DP; Knegtel RM; MacCormick S; Mortimore M; O'Donnell ME; Pinder JL; Reaper PM; Rutherford AP; Wang PS; Young SC; Pollard JR
J Med Chem; 2011 Apr; 54(7):2320-30. PubMed ID: 21413798
[TBL] [Abstract][Full Text] [Related]
11. p53-Independent apoptosis disrupts early organogenesis in embryos lacking both ataxia-telangiectasia mutated and Prkdc.
Gladdy RA; Nutter LM; Kunath T; Danska JS; Guidos CJ
Mol Cancer Res; 2006 May; 4(5):311-8. PubMed ID: 16687486
[TBL] [Abstract][Full Text] [Related]
12. Targeting radiation-resistant hypoxic tumour cells through ATR inhibition.
Pires IM; Olcina MM; Anbalagan S; Pollard JR; Reaper PM; Charlton PA; McKenna WG; Hammond EM
Br J Cancer; 2012 Jul; 107(2):291-9. PubMed ID: 22713662
[TBL] [Abstract][Full Text] [Related]
13. RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells.
Mukhopadhyay UK; Senderowicz AM; Ferbeyre G
Cancer Res; 2005 Apr; 65(7):2872-81. PubMed ID: 15805289
[TBL] [Abstract][Full Text] [Related]
14. Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional.
Lossaint G; Besnard E; Fisher D; Piette J; Dulić V
Oncogene; 2011 Oct; 30(41):4261-74. PubMed ID: 21532626
[TBL] [Abstract][Full Text] [Related]
15. Absence of Wip1 partially rescues Atm deficiency phenotypes in mice.
Darlington Y; Nguyen TA; Moon SH; Herron A; Rao P; Zhu C; Lu X; Donehower LA
Oncogene; 2012 Mar; 31(9):1155-65. PubMed ID: 21765465
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of ATM blocks the etoposide-induced DNA damage response and apoptosis of resting human T cells.
Korwek Z; Sewastianik T; Bielak-Zmijewska A; Mosieniak G; Alster O; Moreno-Villanueva M; Burkle A; Sikora E
DNA Repair (Amst); 2012 Nov; 11(11):864-73. PubMed ID: 23058634
[TBL] [Abstract][Full Text] [Related]
17. BRCA1-BARD1 complexes are required for p53Ser-15 phosphorylation and a G1/S arrest following ionizing radiation-induced DNA damage.
Fabbro M; Savage K; Hobson K; Deans AJ; Powell SN; McArthur GA; Khanna KK
J Biol Chem; 2004 Jul; 279(30):31251-8. PubMed ID: 15159397
[TBL] [Abstract][Full Text] [Related]
18. Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage.
Helt CE; Cliby WA; Keng PC; Bambara RA; O'Reilly MA
J Biol Chem; 2005 Jan; 280(2):1186-92. PubMed ID: 15533933
[TBL] [Abstract][Full Text] [Related]
19. Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1.
Denchi EL; de Lange T
Nature; 2007 Aug; 448(7157):1068-71. PubMed ID: 17687332
[TBL] [Abstract][Full Text] [Related]
20. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
Jette NR; Radhamani S; Arthur G; Ye R; Goutam S; Bolyos A; Petersen LF; Bose P; Bebb DG; Lees-Miller SP
Br J Cancer; 2019 Oct; 121(7):600-610. PubMed ID: 31481733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
